Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T31088 |
CPX-351
Cytarabine/daunonubicin,Vyxeos,CPX 351,Daunonubicin/cytarabine |
Others | Others |
CPX-351 is a Liposomal-encapsulated combination of daunorubicin and cytarabine for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs). |